Table 1 Patients characteristics (n = 89)

Follow-up, years, median (IQR)

15.2 (13.0-18.2)

Patient age, median (IQR)

42.5 (32.5–51.2)

Sex, n (%)

male

female

56 (62.9%)

33 (37.1%)

Diagnosis, n (%)

de novo acute myeloid leukemia

secondary acute myeloid leukemia

68 (76.4%)

21 (23.6%)

Karnofsky performance score

< 80

≥ 80

8 (9.0%)

81 (91.0%)

Hematopoietic cell transplantation-comorbidity index (HCT-CI), n (%)

0

1–2

≥ 3

40 (44.9%)

34 (38.2%)

15 (16.9%)

2017 ELN genetic risk stratification, n (%)

favorable

intermediate

adverse

13 (14.6%)

36 (40.4%)

40 (44.9%)

Disease status at allo-HSCT, n (%)

First complete remission, CR1

CR2, first partial remission, PR1

> CR2, refractory, active disease

31 (34.8%)

32 (36.0%)

26 (29.2%)

Donor type, n (%)

matched sibling donor

matched unrelated donor

mismatched unrelated donor

32 (36.0%)

50 (56.2%)

7 (7.9%)

Stem cell source, n (%)

peripheral blood

bone marrow

82 (92.1%)

7 (7.9%)

Conditioning regimens, n (%)

reduced intensity (4 Gy TBI)

myeloablative intensity (8 Gy TBI, 12 Gy TBI)

31 (34.8%)

58 (65.2%)

Donor age, years, median (IQR)

38.0 (30.5–44.0)

Female donors to male recipients, n (%)

yes

no

14 (15.7%)

75 (84.3%)

Graftversushost disease prophylaxis, n (%)

Cyclosporine, MTX

Cyclosporine, MMF

Post-transplant Cyclophosphamide, Tacrolimus, MMF

57 (64.0%)

30 (33.7%)

2 (2.2%)

Antithymocyte globulin (ATG) *, n (%)

yes

no

61 (68.5%)

28 (31.5%)